Want to see QSI full AI Analyst Report?
QSI Stock Chart & Stats
$1.07
-$0.96(-27.61%)
At close: 4:00 PM EST
$1.07
-$0.96(-27.61%)
Day’s Range― - ―
52-Week Range$0.69 - $3.10
Previous CloseN/A
Volume35.47M
Average Volume (3M)6.07M
Market Cap
$209.57M
Enterprise Value$154.31M
Total Cash (Recent Filing)$127.34M
Total Debt (Recent Filing)$3.71M
Price to Earnings (P/E)―
Beta3.11
Next Earnings
Aug 10, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding197,822,660
10 Day Avg. Volume5,570,890
30 Day Avg. Volume6,074,491
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.99
Price to Sales (P/S)89.30
P/FCF Ratio-2.24
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue83.32
Enterprise Value/Gross Profit208.25
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$2.50Price Target Upside133.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$1.03M
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway And Low LeverageA cash balance of $190.4M and management guidance that this supports operations into 2028 materially lowers near-term financing risk, giving the company time to complete Proteus development, scale manufacturing and pursue commercialization without immediate capital raises.
De-risked Proteus Technology MilestoneDemonstrating end-to-end Proteus sequencing materially de-risks the platform technologically. This milestone strengthens the firm's product moat, supports go-to-market credibility, and improves the likelihood of instrument adoption that drives durable consumable and software revenue streams.
Recurring Consumable-driven Business ModelAn installed-base instrument plus recurring consumables model offers structurally higher-margin, repeatable revenue as adoption grows. If Proteus achieves commercial traction, consumable usage per instrument can generate steady, durable revenue independent of one-time instrument sales.
Bears Say
Very Low And Weakening RevenueDeclining, minimal revenue and negative gross profit indicate the company is not yet monetizing its technology at scale. Persistently weak top-line and negative unit economics limit reinvestment capacity and make successful commercialization and margin recovery essential for long-term viability.
Sustained High Operating Cash BurnStructural operating cash outflows near $90M annually consume runway and force tight prioritization. Even with current cash, continued high burn elevates dilution or cost-cutting risk if commercial ramp underwhelms, making execution speed and expense control critical for solvency.
Dependence On Proteus Launch And Scale-upCommercial success hinges on timely Proteus market entry and efficient manufacturing scale-up. Uncertain customer conversion timing, long-lead parts and assembly optimization risks could delay revenue realization, increase costs, and prolong negative margins and cash burn.
Quantum-Si News
QSI FAQ
What was Quantum-Si Incorporated’s price range in the past 12 months?
Quantum-Si Incorporated lowest stock price was $0.69 and its highest was $3.10 in the past 12 months.
What is Quantum-Si Incorporated’s market cap?
Quantum-Si Incorporated’s market cap is $209.57M.
When is Quantum-Si Incorporated’s upcoming earnings report date?
Quantum-Si Incorporated’s upcoming earnings report date is Aug 10, 2026 which is in 30 days.
How were Quantum-Si Incorporated’s earnings last quarter?
Quantum-Si Incorporated released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.01.
Is Quantum-Si Incorporated overvalued?
According to Wall Street analysts Quantum-Si Incorporated’s price is currently Undervalued.
Does Quantum-Si Incorporated pay dividends?
Quantum-Si Incorporated does not currently pay dividends.
What is Quantum-Si Incorporated’s EPS estimate?
Quantum-Si Incorporated’s EPS estimate is -0.11.
How many shares outstanding does Quantum-Si Incorporated have?
Quantum-Si Incorporated has 197,822,660 shares outstanding.
What happened to Quantum-Si Incorporated’s price movement after its last earnings report?
Quantum-Si Incorporated reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went down -7.551%.
Which hedge fund is a major shareholder of Quantum-Si Incorporated?
Currently, no hedge funds are holding shares in QSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quantum-Si Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (133.64% Upside)
$2.50 (133.64% Upside)
Hedge Fund Trend
Decreased
By 144.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $311.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.55%
12-Months-Change
Fundamentals
Return on Equity
-47.35%
Trailing 12-Months
Asset Growth
-21.34%
Trailing 12-Months
Company Description
Quantum-Si Incorporated
Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry. This system is specifically applied to the field of proteomics, paving the way for next-generation protein sequencing. Established in 2013, Quantum-Si's headquarters are located in Guilford, Connecticut.
QSI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized materially de-risking technical progress for the Proteus platform (successful integrated sequencing, increased amino acid detection, doubled read lengths, PTM strategy) and showed strong early customer engagement and a solid cash runway (~$190M) that supports development through launch. However, near-term revenue remains very small ($258k Q1; ~ $1M outlook for 2026), and the company faces significant R&D/commercialization spend and execution required to scale manufacturing and convert interest into sales. On balance, the advances on Proteus and financial runway are compelling positives, while near-term commercial and burn risks merit monitoring.View all QSI earnings summariesQSI Stock 12 Month Forecast
Average Price Target
$2.50
▲(133.64% Upside)
Technical Analysis
Ownership Overview
22.72% Insiders
6.89% Mutual Funds
<0.01% Other Institutional Investors
61.37% Public Companies and
Individual Investors